R-miniCHOP与R-CHOP在老年弥漫性大B细胞淋巴瘤患者中的比较:一项倾向性匹配的基于人群的研究
该研究基于荷兰癌症登记数据,纳入2014-2020年新诊断的≥65岁弥漫性大B细胞淋巴瘤患者,经倾向性评分匹配后比较384例接受R-miniCHOP与384例接受R-CHOP治疗患者的生存。结果显示R-miniCHOP组2年无进展生存、总生存和相对生存均劣于R-CHOP组,多变量分析中R-miniCHOP组全因死亡风险更高(HR 1.73;95%CI 1.39-2.17)。作者指出R-miniCHOP对多数老年患者有效,但生存劣于R-CHOP,选择治疗时需仔细权衡体能状态。
要点
- R-miniCHOP在DLBCL中的使用从2014年的2%增至2020年的15%。
- 匹配后两组各384例,中位年龄81岁,III-IV期占68%。
- R-miniCHOP组2年PFS 51% vs R-CHOP组68%,OS 60% vs 75%,RS 69% vs 86%,均P<.01。
核心结论
- R-miniCHOP对多数老年患者有效,但生存劣于R-CHOP,选择治疗时需仔细权衡体能状态。
研究设计与样本
- 基于荷兰癌症登记的人群研究,纳入2014-2020年新诊断的≥65岁DLBCL患者,接受≥1周期R-miniCHOP或R-CHOP,生存随访至2022年。
- 经倾向性评分匹配基线特征后,R-miniCHOP组384例与R-CHOP组384例进行比较。
主要发现
- R-miniCHOP在DLBCL中的使用从2014年的2%增至2020年的15%。
- 匹配队列中位年龄81岁,III-IV期占68%,R-(mini)CHOP周期数中位6(范围1-8)。
- 2年PFS为R-miniCHOP组51% vs R-CHOP组68%(p<.01);2年OS为60% vs 75%(p<.01);2年RS为69% vs 86%(p<.01)。
- 多变量分析中,R-miniCHOP组全因死亡风险高于R-CHOP组(HR 1.73;95%CI 1.39-2.17)。
临床怎么用
- 作者认为R-miniCHOP对多数老年患者有效,但生存劣于R-CHOP,选择治疗时需仔细权衡体能状态。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For elderly frail patients with diffuse large B-cell lymphoma (DLBCL), an attenuated chemo-immunotherapy strategy of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-miniCHOP) was introduced as a treatment option as from 2014 onward in the Netherlands. Although R-miniCHOP is more tolerable, reduction of chemotherapy could negatively affect survival compared to R-CHOP. The aim of this analysis was to assess survival of patients treated with R-miniCHOP compared to R-CHOP. DLBCL patients ≥65 years, newly diagnosed in 2014-2020, who received ≥1 cycle of R-miniCHOP or R-CHOP were identified in the Netherlands Cancer Registry, with survival follow-up through 2022. Patients were propensity-score-matched for baseline characteristics. Main endpoints were progression-free survival (PFS), overall survival (OS), and relative survival (RS). The use of R-miniCHOP in DLBCL increased from 2% in 2014 to 15% in 2020. In total, 384 patients treated with R-miniCHOP and 384 patients treated with R-CHOP were included for comparison (median age; 81 years, stage 3-4; 68%). The median number of R-(mini)CHOP cycles was 6 (range, 1-8). The 2-year PFS, OS and RS were inferior for patients treated with R-miniCHOP compared to R-CHOP (PFS 51% vs. 68%, p < .01; OS 60% vs. 75%, p < .01; RS 69% vs. 86%, p < .01). In multivariable analysis, patients treated with R-miniCHOP had higher risk of all-cause mortality compared to patients treated with R-CHOP (HR 1.73; 95%CI, 1.39-2.17). R-miniCHOP is effective for most elderly patients. Although survival is inferior compared to R-CHOP, the use of R-miniCHOP as initial treatment is increasing. Therefore, fitness needs to be carefully weighed in treatment selection.
引用
- Al-Sarayfi D, Brink M, Chamuleau MED, et al. R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study. Am J Hematol. 2023. PMID: 38014799. doi:10.1002/ajh.27151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。